A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
Clinical trial NCT06790693 · RECRUITING
Trial details
- NCT number
- NCT06790693
- Sponsor
- Hoffmann-La Roche
- Status
- RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2025-04-09
- Primary completion
- 2032-05-30
- Enrollment
- 450
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.